3 recruiting, 2 completed. 1 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 1 | Recruiting 1 |
| Phase 3 | 1 | Recruiting 1 |
Follow this drug Literature Review of Off-Label Use trials Research Report on Off-Label Use
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Low Dose Trimethoprim-Sulfamethoxazole for the Treatment of Pneumocystis Jirovecii Pneumonia trimethoprim-sulfamethoxazole - Pneumocystis, Pneumocystis Pneumonia | Phase 3 | Recruiting | Todd C. Lee MD MPH FIDSA | 416 | 2025-11-28 | 2026-02-20 |
| Innovating Access to Novel Therapies Through Standardized Prospective Integration of Response Evaluations (IMPACT-INSPIRE) Off-label or non-standard systemic therapies - Solid Tumor | Recruiting | National Cancer Centre, Singapore | 50 | 2024-09-12 | 2026-05-13 | |
| 18F-FDG PET/CT Guided Reduced-dose Radiotherapy for Nasopharyngeal Carcinoma Reduced dose, Conventional dose, Chemotherapy - Nasopharyngeal Carcinoma | Phase 2 | Recruiting | Taizhou Hospital | 93 | 2022-01-01 | 2023-02-21 |
| Real-world Evaluation of Prevalence of Ocular Adverse Events in Patients With Neovascular (Wet) Agerelated Macular Degeneration (AMD) Who Received Anti-VEGF Agents (IRIS Registry) Aflibercept, Ranibizumab, Bevacizumab - Age-related Macular Degeneration (AMD) | Completed | Novartis Pharmaceuticals | 331541 | 2020-07-15 | 2021-12-21 | |
| Real-world Evaluation of Prevalence of Ocular Adverse Events in Patients With Neovascular (Wet) Age-related Macular Degeneration (AMD) Who Received Anti-vascular Endothelial Growth Factor (VEGF) Agents (Komodo Health) Aflibercept, Ranibizumab, Bevacizumab - Age-related Macular Degeneration (AMD) | Completed | Novartis Pharmaceuticals | 369600 | 2020-07-15 | 2021-12-16 |
Macular Degeneration (2) · Infections (1) · Nasopharyngeal Carcinoma (1) · Pneumocystis Infections (1) · Pneumonia (1) · Pneumonia, Pneumocystis (1)
Novartis Pharmaceuticals (2) · National Cancer Centre, Singapore (1) · Taizhou Hospital (1) · Todd C. Lee MD MPH FIDSA (1)
United States (2) · Canada (1) · China (1) · Singapore (1)
Daniel SW Tan, BSc(Hons), MBBS, MRCP, PhD (1) · Emily G McDonald, MD MSc (1) · Haihua Yang, MD (1) · Todd C Lee, MD MPH FIDSA (1)